DE69300913D1 - Polymorph Terazosin und pharmazeutische Zusammenstellung. - Google Patents

Polymorph Terazosin und pharmazeutische Zusammenstellung.

Info

Publication number
DE69300913D1
DE69300913D1 DE69300913T DE69300913T DE69300913D1 DE 69300913 D1 DE69300913 D1 DE 69300913D1 DE 69300913 T DE69300913 T DE 69300913T DE 69300913 T DE69300913 T DE 69300913T DE 69300913 D1 DE69300913 D1 DE 69300913D1
Authority
DE
Germany
Prior art keywords
terazosin
polymorph
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69300913T
Other languages
English (en)
Other versions
DE69300913T2 (de
Inventor
Glenn A Meyer
John F Bauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69300913(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE69300913D1 publication Critical patent/DE69300913D1/de
Application granted granted Critical
Publication of DE69300913T2 publication Critical patent/DE69300913T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69300913T 1993-04-29 1993-09-28 Polymorph Terazosin und pharmazeutische Zusammenstellung. Revoked DE69300913T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5491793A 1993-04-29 1993-04-29
US08/090,721 US5294615A (en) 1993-04-29 1993-07-13 Terazosin polymorph and pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE69300913D1 true DE69300913D1 (de) 1996-01-11
DE69300913T2 DE69300913T2 (de) 1996-05-02

Family

ID=26733641

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69300913T Revoked DE69300913T2 (de) 1993-04-29 1993-09-28 Polymorph Terazosin und pharmazeutische Zusammenstellung.

Country Status (9)

Country Link
US (2) US5294615A (de)
EP (1) EP0623612B1 (de)
JP (1) JP2755895B2 (de)
DE (1) DE69300913T2 (de)
DK (1) DK0623612T3 (de)
ES (1) ES2089665T3 (de)
GR (1) GR3018433T3 (de)
HK (1) HK124397A (de)
MX (1) MX9306196A (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596109A (en) * 1992-03-24 1997-01-21 Smithkline Beecham Corporation N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph A
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
PT849266E (pt) * 1996-12-20 2007-03-30 Heumann Pcs Gmbh Nova forma polimorfa de mesilato de doxazosina (forma iii)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
ES2435816T3 (es) * 1999-08-03 2013-12-23 Icos Corporation Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
JP2005538031A (ja) * 2000-11-17 2005-12-15 イーライ・リリー・アンド・カンパニー ラクタム化合物
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
TWI353979B (en) 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US7097967B2 (en) * 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
AU2007286186A1 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
CN102321563B (zh) 2011-10-24 2013-04-03 江南大学 一株拟无枝酸菌及利用其全细胞转化制备香草醛的方法
US9096428B2 (en) * 2013-03-08 2015-08-04 Taiwan Semiconductor Manufacturing Company, Ltd. Methods and apparatus for MEMS structure release
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
JP2652272B2 (ja) * 1990-12-31 1997-09-10 住化ファインケム株式会社 １−（４−アミノ−６，７−ジメトキシ−２−キナゾリニル）−４−（２−テトラヒドロフロイル）ピペラジン塩酸塩の新規な結晶体および該結晶体の製造方法

Also Published As

Publication number Publication date
GR3018433T3 (en) 1996-03-31
HK124397A (en) 1997-09-12
US5294615A (en) 1994-03-15
US5362730A (en) 1994-11-08
EP0623612A1 (de) 1994-11-09
JP2755895B2 (ja) 1998-05-25
DK0623612T3 (da) 1996-02-05
EP0623612B1 (de) 1995-11-29
JPH06312984A (ja) 1994-11-08
ES2089665T3 (es) 1996-10-01
DE69300913T2 (de) 1996-05-02
MX9306196A (es) 1994-01-31

Similar Documents

Publication Publication Date Title
DE69300913D1 (de) Polymorph Terazosin und pharmazeutische Zusammenstellung.
FI944832A0 (fi) Farmaseuttinen koostumus
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
FI954767A (fi) Lipofiilisiä lääkeaineita sisältävä farmaseuttinen koostumus
ATA129892A (de) Pharmazeutische zusammensetzung
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
BR9713237B1 (pt) comprimido de liberaÇço controlada de cloridrato de alfuzosina e composiÇço farmacÊutica compreendendo o mesmo.
NO962606D0 (no) Farmasöytisk sammensetning
BR1100824A (pt) Composto e composição farmacêutica
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
BR9408457A (pt) Preparação farmacêutica percutânia
DE69524592D1 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
ITMI932540A0 (it) Composizione farmaceutica
DE4294862T1 (de) Pharmazeutische Komposition
BR9509688A (pt) Composto e composição farmacêutica
DE69614407D1 (de) Pharmazeutische zusammensetzungen
LV11727A (lv) Farmaceitiska kompozicija
DE69434210D1 (de) Pharmazeutische antacidzusammensetzung
FI973280A (fi) Farmaseuttinen koostumus
LV10579A (lv) Farmaceitiska kompozicija
DE69509621D1 (de) Diarylheptanoidderivat und diese enthaltende pharmazeutische Zusammensetzung
BR9605777A (pt) Composição farmacêutica
BR9605131A (pt) Composição farmacêutica
DE69003003D1 (de) Pharmazeutische Zusammensetzung.
BR1101082A (pt) Composto, e, composição farmacêutica

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation